<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="197759">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00516373</url>
  </required_header>
  <id_info>
    <org_study_id>KU36-92</org_study_id>
    <secondary_id>D0810C00002</secondary_id>
    <nct_id>NCT00516373</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)</brief_title>
  <official_title>A Phase I, Pharmacokinetic and Biological Evaluation of a Small Molecule Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP-1), KU-0059436, in Patients With Advanced Tumours.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the safety, tolerability, dose-limiting toxicity (DLT),
      pharmacokinetic-pharmacodynamic profile, and maximum tolerated dose (MTD) of KU-0059436 when
      administered orally to patients with advanced solid tumours. To further evaluate the safety
      and efficacy of KU-0059436 in an expanded cohort of BCRA-enriched population, primarily
      ovarian cancer patients.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 4, 2005</start_date>
  <completion_date type="Anticipated">December 29, 2017</completion_date>
  <primary_completion_date type="Actual">December 17, 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the safety, tolerability, dose-limiting toxicity (DLT), and (MTD) of KU-0059436</measure>
    <time_frame>assessed at each visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective tumour response</measure>
    <time_frame>assessed every 8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Ovarian Neoplasms</condition>
  <condition>BRCA1 Protein</condition>
  <condition>BRCA2 Protein</condition>
  <arm_group>
    <arm_group_label>KU-0059436</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KU-0059436 administered orally twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KU-0059436 (AZD2281)(PARP inhibitor)</intervention_name>
    <description>oral</description>
    <arm_group_label>KU-0059436</arm_group_label>
    <other_name>Olaparib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed malignant advanced solid tumour refractory to standard therapy or for which
             no suitable effective standard therapy exists.

        Exclusion Criteria:

          -  Anti-cancer therapy including chemotherapy, radiotherapy, endocrine therapy,
             immunotherapy or use of other investigational agents within the 4 weeks prior to
             trial entry (or a longer period depending on the defined characteristics of the
             agents used).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jane Robertson, BSc, MBCHB, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Johann De Bono, PhD MRCP FRCR</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Marsden Hospital Trust, London, UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=2678&amp;filename=CSR_Synopsis_D0810C00002(KU36-92).pdf</url>
    <description>CSR_Synopsis_D0810C00002(KU36-92).pdf</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 29, 2017</lastchanged_date>
  <firstreceived_date>August 13, 2007</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>advanced ovarian cancer</keyword>
  <keyword>BRCA 1 protein</keyword>
  <keyword>BRCA 2 protein</keyword>
  <keyword>Poly(ADP ribose)polymerases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Olaparib</mesh_term>
    <mesh_term>Poly(ADP-ribose) Polymerase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
